Display options
Cite
Quirch M, Lee J, Rehman S. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review. J Med Internet Res. 2020;22(8):e20193doi: 10.2196/20193.
Quirch, M., Lee, J., & Rehman, S. (2020). Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review. Journal of medical Internet research, 22(8), e20193. https://doi.org/10.2196/20193
Quirch, Miguel, et al. "Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review." Journal of medical Internet research vol. 22,8 (2020): e20193. doi: https://doi.org/10.2196/20193
Quirch M, Lee J, Rehman S. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review. J Med Internet Res. 2020 Aug 13;22(8):e20193. doi: 10.2196/20193. PMID: 32707537; PMCID: PMC7428145.
Copy Download .nbib Format: NLM
Share it on

J Med Internet Res. 2020 Aug 13;22(8):e20193. doi: 10.2196/20193.

Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.

Journal of medical Internet research

Miguel Quirch, Jeannie Lee, Shabnam Rehman

Affiliations

  1. Texas Tech University Health Sciences Center, Lubbock, TX, United States.

PMID: 32707537 PMCID: PMC7428145 DOI: 10.2196/20193

Abstract

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has challenged medicine and health care on a global scale. Its impact and frightening mortality rate are in large part attributable to the fact that there is a lack of available treatments. It has been shown that in patients who are severely ill, SARS-CoV-2 can lead to an inflammatory response known as cytokine storm, which involves activation and release of inflammatory cytokines in a positive feedback loop of pathogen-triggered inflammation. Currently, cytokine storm is one of the leading causes of morbidity and mortality in SARS-CoV-2, but there is no proven treatment to combat this systemic response.

OBJECTIVE: The aim of this paper is to study the cytokine storm response in SARS-CoV-2 and to explore the early treatment options for patients who are critically ill with the coronavirus disease (COVID-19) in the early stages of the pandemic by reviewing the literature.

METHODS: A literature review was performed from December 1, 2000, to April 4, 2020, to explore and compare therapies that target cytokine storm among SARS-CoV-2 and prior coronavirus cases.

RESULTS: A total of 38 eligible studies including 24 systematic reviews, 5 meta-analyses, 5 experimental model studies, 7 cohort studies, and 4 case reports matched the criteria.

CONCLUSIONS: The severity of the cytokine storm, measured by elevated levels of interleukin-1B, interferon-γ, interferon-inducible protein 10, and monocyte chemoattractant protein 1, was associated with COVID-19 disease severity. Many treatment options with different targets have been proposed during the early stages of the COVID-19 pandemic, ranging from targeting the virus itself to managing the systemic inflammation caused by the virus and the excessive cytokine response. Among the different agents to manage cytokine storm in patients with COVID-19, there is developing support for convalescent plasma therapy particularly for patients who are critically ill or mechanically ventilated and resistant to antivirals and supportive care. Treatment options that were proposed in the beginning phases of the pandemic were multidimensional, and further research is needed to develop a more established treatment guideline.

©Miguel Quirch, Jeannie Lee, Shabnam Rehman. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 13.08.2020.

Keywords: COVID-19; SARS-CoV-2; convalescent plasma therapy; coronavirus; cytokine; cytokine storm; immunology; inflammation; mortality; review; therapy

References

  1. Clin Infect Dis. 2011 Feb 15;52(4):447-56 - PubMed
  2. Clin Ter. 2006 Sep-Oct;157(5):457-68 - PubMed
  3. Cytokine. 2018 Apr;104:8-13 - PubMed
  4. Clin Infect Dis. 2020 Jul 28;71(15):762-768 - PubMed
  5. Crit Care Med. 2015 Jan;43(1):205-25 - PubMed
  6. Life Sci. 2020 Jun 1;250:117583 - PubMed
  7. Best Pract Res Clin Haematol. 2006;19(1):169-89 - PubMed
  8. Ann Lab Med. 2016 Jul;36(4):393-5 - PubMed
  9. Lancet. 2020 Feb 15;395(10223):497-506 - PubMed
  10. Lancet. 2020 Feb 15;395(10223):473-475 - PubMed
  11. Arch Med Res. 2018 Aug;49(6):391-398 - PubMed
  12. JAMA. 2020 Mar 27;: - PubMed
  13. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346 - PubMed
  14. BMJ. 2003 Jun 21;326(7403):1358-62 - PubMed
  15. Ann Oncol. 2020 Jul;31(7):894-901 - PubMed
  16. Drug Discov Ther. 2020;14(1):58-60 - PubMed
  17. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6 - PubMed
  18. Minerva Anestesiol. 2015 Dec;81(12):1298-310 - PubMed
  19. J Med Virol. 2020 Jun;92(6):540-545 - PubMed
  20. BMJ. 2020 Mar 26;368:m1256 - PubMed
  21. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Jun 12;43(6):496-502 - PubMed
  22. Nutrients. 2020 Jan 22;12(2): - PubMed
  23. JAMA. 2020 Mar 27;: - PubMed
  24. JAMA. 2020 Feb 7;: - PubMed
  25. J Microbiol Immunol Infect. 2020 Jun;53(3):368-370 - PubMed
  26. J Pineal Res. 2005 Oct;39(3):287-93 - PubMed
  27. Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975 - PubMed
  28. Clin Exp Immunol. 2004 Apr;136(1):95-103 - PubMed
  29. Clin Immunol. 2020 May;214:108393 - PubMed
  30. Int J Antimicrob Agents. 2020 Jul;56(1):105949 - PubMed
  31. Emerg Infect Dis. 2020 Jun;26(6):1339-1441 - PubMed

Substances

MeSH terms

Publication Types